Jeito Capital has closed its second fund, Jeito II, at more than €1 billion, or about $1.2 billion, giving the Paris-based investor a larger pool of capital for clinical-stage biopharma companies in Europe. The firm says the close exceeds its original target and will support 15 to 20 companies, with per-company investments rising to as much as €150 million.
The new vehicle follows Jeito’s first fund, which raised €534 million in 2021. As with the earlier fund, Jeito said it plans to…
